Extime JCDecaux Airport and Airport International Group sign partnership to transform advertising experience at Queen Alia International Airport in Amman, Jordan
Extime JCDecaux Airport and Airport International Group sign partnership to transform advertising experience at Queen Alia International Airport in Amman, Jordan
Paris, May 26th, 2025 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announces that Extime JCDecaux Airport has been granted on May 20th by Airport International Group (AIG) the contract to operate advertising activities from August 1st, 2025 onwards at Queen Alia International Airport in Amman, Jordan, which welcomes over nine million travellers annually.
Leveraging the global expertise of JCDecaux, along with its established presence in the Middle East especially in other major airport hubs of the region, Extime JCDecaux Airport will develop a new advertising offer, enhancing both brand engagement and passenger journey at Queen Alia International Airport. Extime JCDecaux Airport will build on the innovative technologies developed by JCDecaux and its sustainable development strategy, around three main pillars:
Advanced Network Integration and use of cutting-edge technologies The deployment of a new broadcasting system, ISO 27001 certified, based on highly secure infrastructures will connect all digital assets across the airport and ensure real-time synchronisation, seamless content delivery, and operational efficiency. In a very practical sense, it will be possible to schedule and synchronise advertising content according to flight schedules. Continuous 24/7 monitoring will optimise reliability and system performance, demonstrating Extime JCDecaux Airport's dedication to upholding high standards of quality and safety.
Sustainable Transformation of Static AssetsIn alignment with Queen Alia International Airport's CSR and Climate strategy, Extime JCDecaux Airport will implement eco-friendly changes to static media platforms. Energy-efficient LED panels will replace traditional lighting in static lightboxes, significantly reducing energy consumption and operational costs.
Robust and Sustainable Exterior AssetsExtime JCDecaux Airport is committed to expanding its media footprint beyond terminal interiors with the phased introduction of Skytouch portrait static assets in exterior areas. These installations are designed with safety and sustainability in mind. The integration of LED lighting systems will enhance visibility while supporting energy efficiency goals, positioning Extime JCDecaux Airport as a pioneer in responsible outdoor advertising infrastructure.
Nicolas Deviller, Airport International Group CEO, said: 'For us, every element of the airport journey - visual, operational and emotional - reflects our brand promise 'Feels Like Home'. As the first point of contact for millions arriving in Jordan, QAIA plays a vital role in shaping perceptions from the moment passengers arrive. Through our collaboration with Extime JCDecaux Airport, we are introducing a world-class visual environment that seamlessly combines innovation, sustainability and impactful brand storytelling. These enhancements are not only designed to create value for advertisers, but more importantly, to enrich the passenger experience at every touchpoint - making it more welcoming, engaging and aligned with the top-tier standards of Jordan's prime gateway to the world.'
Isabelle Fourmentin, Extime JCDecaux Airport Managing Director, said: 'We are delighted to start this new chapter in Extime JCDecaux Airport advertising activities at Queen Alia International Airport and I would like to warmly thank our partner AIG for their trust and support. Our plan is to develop an eco-friendly advertising platform based on innovative, high-performance media solutions for advertisers, enhancing both brand advertising experiences and passenger journey.'
Jean-Charles Decaux, Co-CEO of JCDecaux, said: 'We are delighted with the extension of Extime JCDecaux Airport's advertising activities to Queen Alia International Airport in Amman, with the support of AIG that we kindly thank. This new contract is a recognition of the expertise of the Extime JCDecaux Airport teams and their ability to deploy cutting-edge solutions for advertisers, contributing to the operational excellence of this airport. Drawing on the know-how of JCDecaux's teams, which operate 157 advertising airport contracts around the world, including renowned hubs in the Middle East, Extime JCDecaux Airport will contribute, in collaboration with AIG, to the transformation of Queen Alia International's airport environment, respecting high quality and sustainable development standards.'
Key Figures for JCDecaux
2024 revenue: €3,935.3m
N°1 Out-of-Home Media company worldwide
A daily audience of 850 million people in more than 80 countries
1,091,811 advertising panels worldwide
Present in 3,894 cities with more than 10,000 inhabitants
12,026 employees
JCDecaux is listed on the Eurolist of Euronext Paris and is part of the SBF 120 and CAC Mid 60 indexes
JCDecaux's Group carbon reduction trajectory has been approved by the SBTi and the company has joined the Euronext Paris CAC® SBT 1.5° index
JCDecaux is recognised for its extra-financial performance in the CDP (A), MSCI (AAA), Sustainalytics (13.1), and has achieved Gold Medal status from EcoVadis
1st Out-of-Home Media company to join the RE100
Leader in self-service bike rental scheme: pioneer in eco-friendly mobility
N°1 worldwide in street furniture (629,737 advertising panels)
N°1 worldwide in transport advertising with 157 airports and 257 contracts in metros, buses, trains and tramways (340,848 advertising panels)
N°1 in Europe for billboards (83,472 advertising panels worldwide)
N°1 in outdoor advertising in Europe (736,310 advertising panels)
N°1 in outdoor advertising in Asia-Pacific (178,010 advertising panels)
N°1 in outdoor advertising in Latin America (89,526 advertising panels)
N°1 in outdoor advertising in Africa (22,490 advertising panels)
N°1 in outdoor advertising in the Middle East (20,689 advertising panels)
About Extime JCDecaux AirportExtime JCDecaux Airport, an expert in airport advertising, provides high-performance, tailored media solutions to create unforgettable brand experiences at Paris-Charles de Gaulle, Paris-Orly, Paris-Le Bourget, and now Amman's Queen Alia International Airport. Extime JCDecaux Airport is dedicated to enriching the advertising landscape in airports for the benefit of both travellers and brands. The brand is a joint venture between JCDecaux, N°1 Out-of-Home Media company worldwide, and Groupe ADP, world leader in airport operations.
For more information about JCDecaux, please visit jcdecaux.com. Join us on X, LinkedIn, Facebook, Instagram and YouTube.
: Albert Asséraf+33 (0) 1 30 79 79 10 – albert.asseraf@jcdecaux.com
: Rémi Grisard+33 (0) 1 30 79 79 93 – remi.grisard@jcdecaux.com
Attachment
26-05-2025 # Amman_UK
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Dassault Systèmes: Doubling EPS by 2029, 3D UNIV+RSES creating new growth opportunities
Press ReleaseVELIZY-VILLACOUBLAY — June 6, 2025 Dassault Systèmes: Doubling EPS by 2029,3D UNIV+RSES creating new growth opportunities Dassault Systèmes (Euronext Paris: FR0014003TT8, hosts its 2025 Capital Markets Day at its headquarters in Vélizy-Villacoublay, France, today, June 6, 2025. The event, dedicated to financial analysts and investors, features a series of presentations by the Company's executive management. It highlights how 3D UNIV+RSES mark a fundamental shift, providing the next generation of virtual-plus-real (V+R) environment. This unlocks the full potential for clients to leverage Gen AI, creating new possibilities and reaching meaningful productivity gains while protecting their IP. Dassault Systèmes elevates the value creation with 3D UNIV+RSES and demonstrates the reasons to believe across Industrial innovation, Mainstream and Life Sciences. Together, these drivers form a coherent and powerful roadmap, positioning the Company to fully capitalize on significant mid to long-term opportunities. Dassault Systèmes updates its mid-term financial ambition to double non-IFRS diluted EPS by 2029. This allows the adoption of 3D UNIV+RSES to deliver its full potential. Commencing at 12:45 PM London time / 7:45 AM New York time / 1:45 PM Paris time, the event will be webcast live and recorded. Both the live sessions and replays can be accessed via Dassault Systèmes' investor website: The on-demand webcast of the event will be available from June 9, 2025. Pascal Daloz, Dassault Systèmes' Chief Executive Officer, commented: 'At today's Capital Markets Day, we unveil the most strategic evolution in Dassault Systèmes' history. AI for industry becomes our compass, while our next-generation value proposition – 3D UNIV+RSES – defines the next growth cycle of our company. We are entering a new era: the Generative Economy, where value creation lies at the intersection of the Virtual and the Real – V+R. It is in this hybrid space that tomorrow takes shape and our mission is to empower our customers to imagine, to create and to operate in this hybrid world. From life-saving therapies to next-generation mobility and resilient, sustainable infrastructure, 3D UNIV+RSES are not just transforming how industry functions – it is redefining what is possible. We are delivering the virtual twin of everything for everyone, infused with trusted AI, to reinvent products, enterprises and business models through the convergence of the Virtual and the 3DEXPERIENCE platform now becomes the engine of the Generative Economy, enabling creation, management and amplification of knowledge, know-how and intellectual property – the new currency of progress. With 3D UNIV+RSES, we are not simply envisioning the future of industry – we are building it, unlocking new performances, new possibilities and magic experiences. A future where AI is not artificial but augmented, scientific, trustable and deeply human.' Rouven Bergmann, Dassault Systèmes' Chief Financial Officer, commented: [diluted EPS ('EPS') on a non-IFRS basis] 'We are building a company for the long term – one that delivers durable, high-quality growth powered by a loyal and expanding client base. Our ambition is clear: to double our earnings per share, and to keep doing so. The 3DEXPERIENCE platform is a strategic advantage. In the era of AI, it accelerates knowledge creation, unifies collaboration through a single source of truth, and unleashes the full potential of human talent. With the launch of 3D UNIV+RSES, we are unlocking a new phase of cloud adoption and customer engagement. As a result, we are extending our financial horizon to double EPS by 2029. This shift reflects three key factors: a gradual acceleration in top-line growth, the scale-up of 3D UNIV+RSES, and continued strategic capital allocation, including targeted M&A. Every move we make is guided by a single principle: creating long-term, sustainable value for our clients, our shareholders and our people, contributing to our EPS and cash generation. We are aligned and positioned to capture the full value of this opportunity.' Investor Relations Events Second Quarter 2025 Earnings Release: July 24, 2025 Third Quarter 2025 Earnings Release: October 23, 2025 Fourth Quarter 2025 Earnings Release: February 11, 2026 First Quarter 2026 Earnings Release: April 23, 2026 Forward-looking Information Statements herein that are not historical facts but express expectations or objectives for the future, including but not limited to statements regarding the Group's non-IFRS financial performance objectives are forward-looking statements. Such forward-looking statements are based on Dassault Systèmes management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results or performances may differ materially from those in such statements due to a range of Group's actual results or performance may be materially negatively affected by numerous risks and uncertainties, as described in the 'Risk Factors' section 1.9 of the 2024 Universal Registration Document ('Document d'enregistrement universel') filed with the AMF (French Financial Markets Authority) on March 18, 2025, available on the Group's website particular, please refer to the risk factor 'Uncertain Global Environment' in section 1.9.1.1 of the 2024 Universal Registration Document set out below for ease of reference: 'In light of the uncertainties regarding economic, business, social, health and geopolitical conditions at the global level, Dassault Systèmes' revenue, net earnings and cash flows may grow more slowly, whether on an annual or quarterly basis, mainly due to the following factors: the deployment of Dassault Systèmes' solutions may represent a large portion of a customer's investments in software technology. Decisions to make such an investment are impacted by the economic environment in which the customers operate. Uncertain global geopolitical, economic and health conditions and the lack of visibility or the lack of financial resources may cause some customers, e.g. within the automotive, aerospace, energy or natural resources industries, to reduce, postpone or cancel their investments, or to reduce or not renew ongoing paid maintenance for their installed base, which impact larger customers' revenue with their respective sub-contractors; the political, economic and monetary situation in certain geographic regions where Dassault Systèmes operates could become more volatile and negatively affect Dassault Systèmes' business, and in particular its revenue, for example, due to stricter export compliance rules or the introduction of new customs barriers or controls on the exchange of goods and services; continued pressure or volatility on raw materials and energy prices could also slow down Dassault Systèmes' diversification efforts in new industries; uncertainties regarding the extent and duration of costs inflation could adversely affect the financial position of Dassault Systèmes; and the sales cycle of the Dassault Systèmes' products – already relatively long due to the strategic nature of such investments for customers – could further lengthen. The occurrence of crises – health and political crises in particular – could have consequences both for the health and safety of Dassault Systèmes' employees and for the Company. It could also adversely impact the financial situation or financing and supply capabilities of Dassault Systèmes' existing and potential customers, commercial and technology partners, some of whom may be forced to temporarily close sites or to cease operations. A deteriorating economic environment could generate increased price pressure and affect the collection of receivables, which would negatively affect Dassault Systèmes' revenue, financial performance and market position. Dassault Systèmes makes every effort to take into consideration this uncertain outlook. Dassault Systèmes' business results, however, may not develop as anticipated. Furthermore, due to factors affecting sales of Dassault Systèmes' products and services, there may be a substantial time lag between an improvement in global economic and business conditions and an upswing in the Company's business results. Non-IFRS Financial Information Readers are cautioned that the supplemental non-IFRS financial information presented in this press release is subject to inherent limitations. It is not based on any comprehensive set of accounting rules or principles and should not be considered in isolation from or as a substitute for IFRS measurements. The supplemental non-IFRS financial information should be read only in conjunction with the Company's consolidated financial statements prepared in accordance with IFRS. Furthermore, the Group's supplemental non-IFRS financial information may not be comparable to similarly titled 'non-IFRS' measures used by other companies. Specific limitations for individual non-IFRS measures are set forth in the Company's 2024 Universal Registration Document filed with the AMF on March 18, 2025. FOR MORE INFORMATION Dassault Systèmes' 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions: DASSAULT SYSTÈMESDassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370 000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit Dassault Systèmes Investor Relations Team FTI ConsultingBeatrix Martinez: +33 1 61 62 40 73 Arnaud de Cheffontaines: +33 1 47 03 69 Jamie Ricketts : +44 20 3727 1600investors@ Dassault Systèmes Press ContactsCorporate / France Arnaud MALHERBE +33 (0)1 61 62 87 73 © Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval. Attachment Dassault Systèmes: Doubling EPS by 2029, 3D UNIV+RSES creating new growth opportunitiesSign in to access your portfolio
Yahoo
a day ago
- Yahoo
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, although more robust with the full dose Six-month data confirm full dose selection for pivotal Phase 3 trial Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3 study in children, which the Company expects to initiate in the first quarter of 2026, with the objective of extending the product label to this age group. Trial VLA1553-221's six-month results were in line with the initial data the Company reported for this trial in January 20251. A full dose (licensed IXCHIQ® formulation and presentation) elicited a more robust immune response in children aged one to eleven years at Day 15 and Day 180 post vaccination compared to a half dose. Overall, the immunological response profile was in line with what was previously observed in adults and adolescents234567. The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180. VLA1553 was well tolerated in children aged one to eleven years regardless of the dose or previous CHIKV infection. No safety concerns were identified. The comparability of the VLA1553 doses tested in terms of safety and tolerability, along with the more pronounced immune response of the full dose observed for all age groups tested in children up to Day 180 post-vaccination, support the selection of the full dose for use in this population. Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, 'The six months persistence and safety data in children are aligned with the robust antibody response and safety profile we reported in adolescents after a single vaccination. Considering the significant risk chikungunya poses to individuals living in or traveling to endemic areas, it's crucial to ensure that the vaccine is accessible to people of all ages and capable of potentially offering long-term protection from a single shot. This is especially important in Low- and Middle-Income countries (LMICs) where access to vaccines is often limited.' Brazil has reported the highest number of chikungunya cases worldwide, with over one million cases between January 2019 and July 20248, followed by India with 370,000 cases during the same period. This number is rapidly increasing due to the current outbreak in the Indian states of Maharashtra and Telangana, for which the U.S. Centers for Disease Control and Prevention (CDC) issued a travel notice after identifying higher-than-expected numbers of chikungunya cases in returning travelers9. Additionally, two outbreaks are ongoing on the French islands of La Reunion and Mayotte10. About ChikungunyaChikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years11. In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas12. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas13 and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.14 About Phase 2 Trial VLA1553-221 VLA1553-221 is a multi-center, randomized, observer-blinded, dose response Phase 2 clinical trial in 304 healthy children aged one to eleven years. The trial is performed at three trial sites in the Dominican Republic and Honduras. The primary and secondary objectives of the trial are to evaluate the safety and immunogenicity of two different dose levels of Valneva's single-shot chikungunya vaccine. Participants were randomized 2:2:1 to receive either a full dose (licensed IXCHIQ® formulation and presentation) or a half dose of the vaccine, or an active control (Nimenrix). Additional information, including a detailed description of the trial design, eligibility criteria and investigator sites, is available at (Identifier: NCT06106581). About Valneva SEWe are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world's first and only chikungunya vaccine, as well as certain third-party from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at About CEPICEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organizations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI's pandemic-beating five-year plan for 2022-2026 is the '100 Days Mission' to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Learn more at Follow us on X (@CEPIvaccines), LinkedIn and Facebook. About Horizon EuropeHorizon Europe — #HorizonEU — is the European Union's flagship Research and Innovation programme, part of the EU-long-term Multiannual Financial Framework (MFF) with a budget of €95,5 billion to spend over a seven-year period (2021-2027). Under Horizon Europe, health research will be supported with the aim to find new ways to keep people healthy, prevent diseases, develop better diagnostics and more effective therapies, use personalised medicine approaches to improve healthcare and wellbeing, and take up innovative health technologies, such as digital ones. Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP Global Communications & European Investor RelationsM +33 (0)6 4516 Joshua Drumm, Global Investor RelationsM +001 917 815 Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - Valneva2 Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate - Valneva3 Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate - Valneva4 Lancet Paper: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate - Valneva6 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate - Valneva7 Lancet Paper: 12 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). Last accessed 01 Aug 2023.14 Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas ( Attachment 2025_06_05_VLA1553-221_6M_Persistence_Data_PR_EN_FinalError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
FORVIA: Total number of voting rights and shares forming the share capital
Nanterre, 5 June 2025 Total number of voting rights and shares forming the share capital (Article L. 233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of the French Financial Markets Authority)__________________ Trading place: Euronext Paris Compartment: A ISIN Code: FR0000121147 LEI Code: 969500F0VMZLK2IULV85 Date Number of shares Total number of theoretical voting rights (1) Total number of exercisable voting rights (2) 31 May 2025 197,089,340 231,328,050 218,964,652 (1) In accordance with the provisions of Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of voting rights (theoretical) is calculated on the basis of all the shares to which voting rights are attached, including the shares deprived of voting rights. (2) Exercisable voting rights = total number of voting rights attached to the total number of shares less shares deprived of voting rights. Inclusion in the bylaws of a clause that requires crossing thresholds declaration in addition to that related to legal thresholds: yes. Attachment Déclaration nombre d'actions et droits de vote au 31 mai 2025 ENGError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
